Status: Recruiting
Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
This is a phase 2 single-arm, open-label clinical trial designed to evaluate the efficacy and safety of tarlatamab in patients with relapsed extrapulmonary neuroendocrine carcinoma (EPNEC) who have previously received platinum-based first-line chemotherapy. Participants will receive tarlatamab on Cycle 1 Day 1 (C1D1), Day 8 (C1D8), and Day 15 (C1D15), followed by administration every two weeks thereafter. No placebo control is included in this study.
Participants needed: 60
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Inkeun ParkUpdated: Apr 13, 2026Locations: 4
Eligibility criteria
Age ≥19 years at the time of signing the informed consent. [+10]
Subject is asymptomatic from brain metastases [+41]